Skip to main content Help with accessibility Skip to main navigation

Denosumab

Indication

Prevention of osteoporotic fractures in postmenopausal women (NICE TA204)
MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA Drug Safety Update - Denosumab: updated recommendations
MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)
Amber level 1

Brand:

Prolia®

Nice TA:

204

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

Recommendation

LSCMMG Recommendation:

Amber level 1

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

Denosumab Shared Care 60mg

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Amber 0
Amber 1
Amber 1
Amber 0
Amber 1
Amber 1
Amber 0
Amber 0
What do the colours mean?

Last Updated: 01 - Nov - 2013